慢性 骨髄 単 球 性 白血病。 慢性骨髄性白血病

慢性骨髄性白血病の症状と病期|慢性骨髄性白血病(CML)を学ぶ|がんを学ぶ ファイザー

♨European LeukemiaNet recommendations for the management of chronic myeloid leukemia : 2013. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia : results from the BELA trial. Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008 : a population-based study. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Lyon, IARC ; 2017 : pp16-27. Long-term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels : the JALSG CML202 study. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia : the ANAHYDRET Study, a randomized controlled trial. Pérez B, Kosmider O, Cassinat B, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. Final 5-year study results of DASISION : The dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. Polycythemia vera : scientific advances and current practice. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. NCCN clinical practice guideline in oncology. Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chro-mosome-positive leukemias treated with bosutinib. Hematology Am Soc Hematol Educ Program. No treatment for low-risk thrombocythaemia : results from a prospective study. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. Clinical features and outcomes of patients with primary myelofibrosis in Japan : report of a 17-year nationwide survey by the Idiopathic Disorders of Hematopoietic Organs Research Committee of Japan. Molecular monitoring in CML and the prospects for treatment-free remissions. Essential thrombocythemia beyond the first decade : life expectancy, long-term complication rates, and prognostic factors. Introduction and overview of the classification of myeloid neoplasms. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment : the EUTOS score. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Lyon, IARC ; 2017 : pp30-6. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of highrisk, Philadelphia-positive chronic myeloid leukemia : a European LeukemiaNet Study. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues ed. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Long-term follow-up of 386 consecutive patients with essential thrombocythemia : safety of cytoreductive therapy. Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy2. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase : 5-year update of the randomized ENESTnd trial. Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. A prognostic model to predict survival in 867 World Health Organization-defined essential hrombocythemia at diagnosis : a study by the International Working Group on Myelofibrosis Research and Treatment. Ismael O, Shimada A, Hama A, et al. The effect of anabolic steroids on anemia in myelofibrosis with myeloid metaplasia : retrospective analysis of 39 patients in Japan. DIPSS plus : a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. Long term outcomes of imatinib treatment for chronic myeloid leukemia. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia. Writing Committee for the Collaborative CML Prognostic Factors Project Group. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. Splenic irradiation provides transient palliation for symptomatic splenomegaly associated with primary myelofibrosis : a report on 14 patients. Standardized definitions of molecular response in chronic myeloid leukemia. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. Shiba N, Hasegawa D, Park MJ, et al. Chronic myeloid leukemia Version 3. Chronic myeloid leukaema, BCR-ABL1-positive. Chronic myeloid leukemia : an update of concepts and management recommendations of European LeukemiaNet.。

19
。 。

慢性骨髄性白血病(CML)

😆。 。 。

19
。 。

慢性骨髄性白血病の症状と病期|慢性骨髄性白血病(CML)を学ぶ|がんを学ぶ ファイザー

💓。

。 。

慢性骨髄性白血病(CML)

💕。 。

14
。 。

白血病の種類について

🚀。 。

10
。 。

慢性骨髄単球性白血病 概要

👉。 。 。

4

慢性骨髄性白血病 (まんせいこつずいせいはっけつびょう)

⚛。 。

17

治療が劇的に進歩した「慢性骨髄性白血病」 8割以上は長期生存:名医が解説! 最新治療トレンド:日経Gooday(グッデイ)

🤑。 。 。

13
。 。

慢性骨髄性白血病の段階別の症状、検査、治療法について解説

☣。 。 。

。 。